Abstract
Cytokines that are involved in inflammation are related to blood coagulation, which could indirectly affect warfarin dose requirements. This study aimed to examine the effects of inflammatory cytokine gene polymorphisms on warfarin dose requirements for Korean patients with mechanical heart valves. In total, 191 patients with mechanical heart valves who were on warfarin anticoagulation therapy and maintained INR levels of 2–3 for three consecutive occasions were retrospectively followed up. In addition to vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 (CYP) 2C9 polymorphisms, the interferon-γ, interleukin-1β (IL1B), interleukin-6, interleukin-10, transforming growth factor-β1 (TGFB1), tumor necrosis factor-α, and C-reactive protein genotypes were determined. The predictive contribution of age, VKORC1, and CYP2C9 to variability was 46.0 %. The addition of IL1B and TGFB1 polymorphisms increased the R 2 to 48.8 % for stable dose requirements, and significantly higher doses were found, especially when the TGFB1 CC genotype was combined with the IL1B TT genotype. Based on the results, it was concluded that inflammatory cytokine genes, such as TGFB1 and IL1B, can be predictive variables for stable warfarin doses in Korean patients.
Similar content being viewed by others
References
Almeida, O.P., P.E. Norman, R. Allcock, F. van Bockxmeer, G.J. Hankey, K. Jamrozik, and L. Flicker. 2009. Polymorphisms of the CRP gene inhibit inflammatory response and increase susceptibility to depression: The Health in Men Study. International Journal of Epidemiology 38: 1049–1059.
Ansell, J., J. Hirsh, L. Poller, H. Bussey, A. Jacobson, and E. Hylek. 2004. The pharmacology and management of the vitamin K antagonists: The seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 126: 204S–233S.
Awad, M.R., A. El-Glamel, P. Haselton, D.M. Turner, P.J. Sinnott, and I.V. Hutchinson. 1998. Genotypic variation in the transforming growth factor-beta 1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66: 1014–1020.
Bennermo, M., C. Held, F. Green, L.E. Strandberg, C.G. Ericsson, L.O. Hansson, H. Watkins, A. Hamsten, and P. Tornvall. 2004. Prognostic value of plasma interleukin-6 concentrations and the 174 G>C and 572 G>C promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis. Atherosclerosis 174: 157–163.
Biasucci, L.M., G. Liuzzo, A. Buffon, and A. Maseri. 1999. The variable role of inflammation in acute coronary syndromes and in restenosis. Seminars in interventional cardiology 4: 105–110.
Bidwell, J., L. Keen, G. Gallacher, R. Kimberly, T. Huizinga, M.F. McDermott, J. Oksenberg, J. McNicholl, F. Pociot, C. Hardt, and S. D’Alfonso. 1999. Cytokine gene polymorphism in human disease: Online databases, supplement 1. Genes and Immunity 1: 3–19.
Bogaty, P., P. Poirier, S. Simard, L. Boyer, S. Solymoss, and G.R. Dagenais. 2001. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 103: 3062–3068.
Caldwell, M.D., T. Awad, J.A. Johnson, B.F. Gage, M. Falkowski, P. Gardina, J. Hubbard, Y. Turpaz, T.Y. Langaee, C. Eby, C.R. King, A. Brower, J.R. Schmelzer, I. Glurich, H.J. Vidaillet, S.H. Yale, K. Qi Zhang, R.L. Berg, and J.K. Burmester. 2008. CYP4F2 genetic variant alters required warfarin dose. Blood 111: 4106–4112.
Casas, J.P., T. Shah, A.D. Hingorani, J. Danesh, and M.B. Pepys. 2008. C-reactive protein and coronary heart disease: A critical review. Journal of Internal Medicine 264: 295–314.
Cho, H.J., K.H. Sohn, H.M. Park, K.H. Lee, B. Choi, S. Kim, J.S. Kim, Y.K. On, M.R. Chun, H.J. Kim, J.W. Kim, and S.Y. Lee. 2007. Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics 8: 329–337.
Cicala, C., and G. Cirino. 1998. Linkage between inflammation and coagulation: An update on the molecular basis of the crosstalk. Life Sciences 62: 1817–1824.
Cresey, A.A., A.C. Chang, L. Feigen, T.C. Wün, F.B. Taylor Jr, and L.B. Hinshaw. 1993. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. Journal of Clinical Investigation 91: 2850–2856.
Crobu, F., L. Palumbo, E. Franco, S. Bergerone, S. Carturan, S. Guarrera, S. Frea, G. Trevi, A. Piazza, and G. Matullo. 2008. Role of TGF-β1 haplotypes in the occurrence of myocardial infarction in young Italian patients. BMC Medical Genetics 9: 1–7.
De Jonge, E., P.E. Dekkers, A.A. Creasey, C.E. Hack, S.K. Paulson, A. Karim, J. Kesecioglu, M. Levi, S.J. van Deventer, and T. van Der Poll. 2000. Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 95: 1124–1129.
Esmon, C.T. 1994. Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Clinical Haematology 7: 453–468.
Esmon, C.T. 2002. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. Journal of Experimental Medicine 196: 561–564.
Ford, E.S., and W.H. Giles. 2000. Serum C-reactive protein and fibrinogen concentrations and self-reported angina pectoris and myocardial infarction: Findings from National Health and Nutrition Examination Survey III. Journal of Clinical Epidemiology 53: 95–102.
Frangogiannis, N.G., C.W. Smith, and M.L. Entman. 2002. The inflammatory response in myocardial infarction. Cardiovascular Research 53: 31–47.
Fuster, V., L. Badimon, J.J. Badimon, and J.H. Chesebro. 1992. The pathogenesis of coronary artery disease and the acute coronary syndrome. New England Journal of Medicine 326: 242–250.
Hanson, G. 2005. Inflammation, atherosclerosis, and coronary artery disease. New England Journal of Medicine 352: 1685–1695.
Hutchinson, J.V., V. Pravica, and P.J. Sinnot. 1998. Genetic regulation of cytokine synthesis: Consequences for acute and chronic organ allograft rejection. Graft 1: 15–21.
Kobayashi, M., K. Shimada, and T. Ozawa. 1990. Human recombinant interleukin-1 beta and tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. Journal of Cellular Physiology 144: 383–390.
Lazo-Langner, A., G.A. Knoll, P.S. Wells, N. Carson, and M.A. Rodger. 2006. The risk of dialysis access thrombosis is related to the transforming growth factor-beta1 production haplotype and is modified by polymorphisms in the plasminogen activator inhibitor-type 1 gene. Blood 108: 4052–4058.
Lee, K.E., B.C. Chang, H.O. Kim, I.K. Yoon, N.R. Lee, H.Y. Park, and H.S. Gwak. 2012. Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves. Therapeutic Drug Monitoring 34: 275–282.
Levi, M., T. Van der Poll, and H.R. Buller. 2004. Bidirectional relation between inflammation and coagulation. Circulation 109: 2698–2704.
Levi, M., and T. Van der Poll. 2005. Two-way interactions between inflammation and coagulation. Trends in Cardiovascular Medicine 15: 254–259.
Libby, P. 2002. Inflammation in atherosclerosis. Nature 420: 868–874.
Libby, P., P.M. Ridker, and A. Maseri. 2002. Inflammation and atherosclerosis. Circulation 105: 1135–1143.
Lindahl, B., H. Toss, A. Siegbahn, P. Venge, and L. Wallentin. 2001. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. The New England Journal of Medicine 343: 1139–1147.
Lindmark, E., E. Diderholm, L. Wallentin, and A. Siegbahn. 2001. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: Effects of an early invasive or non invasive strategy. Journal of American Medical Association 286: 2107–2113.
Manginas, A., A. Tsiavou, A. Chiadaroglou, G. Giamouzis, D. Degiannis, D. Panagiotakos, and D.V. Cokkinos. 2008. Inflammatory cytokine gene variants in coronary artery disease patients in Greece. Coronary Artery Disease 19: 575–582.
Minkelen, R.V., M.C. De Visser, J.J. Houwing-Duistermaat, H.L. Vos, R.M. Bertina, and F.R. Rosendaal. 2007. Haplotypes of IL1B, IL1RN, IL1R1, and IL1R2 and the risk of venous thrombosis. Arteriosclerosis Thrombosis and Vascular Biology 27: 1486–1491.
Nawroth, P.P., and D.M. Stern. 1986. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. Journal of Experimental Medicine 163: 740–745.
Ognjanovic, S., J. Yamamoto, B. Saltzman, A. Franke, M. Ognjanovic, L. Yokochi, T. Vogt, R. Decker, and L. Le Marchand. 2010. Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multiethnic population. Cancer Causes and Control 21: 1131–1138.
Olivieri, F., R. Antonicelli, M. Cardelli, F. Marchegiani, L. Cavallone, E. Mocchegiani, and C. Franceschi. 2006. Genetic polymorphisms of inflammatory cytokines and myocardial infarction in the elderly. Mechanisms of Ageing and Development 127: 552–559.
Opal, S.M., and C.T. Esmon. 2003. Bench-to-bed-side review: Functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Critical Care 7: 23–38.
Orbe, J., C. Chorda, R. Montes, and J.A. Paramo. 1999. Changes in the fibrinolytic components of cultured human umbilical vein endothelial cells induced by endotoxin, tumor necrosis factor-alpha and interleukin-1 alpha. Haematologica 84: 306–311.
Pravica, V., C. Perrey, A. Stevenes, J.H. Lee, and I.V. Hutchinson. 2000. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: Absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Human Immunology 61: 863–866.
PRIME Study Group. 2003. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: The PRIME Study. Arteriosclerosis Thrombosis and Vascular Biology 23: 1255–1261.
Real, J.M.F., F. Vendrell, C. Richart, C. Gutierrez, and W. Ricart. 2001. Platelet account and interleukin-6 gene polymorphism in healthy subjects. BMC Medical Genetics 2: 6–11.
Shah, P.K. 2007. Molecular mechanisms of plaque instability. Current Opinion in Lipidology 18: 492–499.
Tumor, D.M., D.M. Williams, D. Sankaran, M. Lazarus, P.J. Sinnott, and I.V. Hutchinson. 1997. An investigation of polymorphism in the interleukin-10 gene. European Journal of Immunogenetics 24: 1–8.
Wilson, A.G., J.A. Symon, T. McDowell, H.O. McDevitt, and G.W. Duff. 1997. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proceedings of the National Academy of Sciences of the United States of America 94: 3195–3199.
Conflict of interest
We declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
In Kyung Yoon and Yun Jung Choi have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Yoon, I.K., Choi, Y.J., Chang, B.C. et al. Effects of inflammatory cytokine gene polymorphisms on warfarin maintenance doses in Korean patients with mechanical cardiac valves. Arch. Pharm. Res. 37, 752–759 (2014). https://doi.org/10.1007/s12272-013-0221-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-013-0221-4